articleNew England Journal of MedicineSep 21, 2006BRONZE OA

Intracoronary Injection of Mononuclear Bone Marrow Cells in Acute Myocardial Infarction

Oslo University Hospital · Center for Clinical Research (United States) · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Previous studies have shown improvement in left ventricular function after intracoronary injection of autologous cells derived from bone marrow (BMC) in the acute phase of myocardial infarction. We designed a randomized, controlled trial to further investigate the effects of this treatment.

Methods

Patients with acute ST-elevation myocardial infarction of the anterior wall treated with percutaneous coronary intervention were randomly assigned to the group that underwent intracoronary injection of autologous mononuclear BMC or to the control group, in which neither aspiration nor sham injection was performed. Left ventricular function was assessed with the use of electrocardiogram-gated single-photon-emission computed tomography (SPECT) and echocardiography at baseline and magnetic resonance imaging (MRI) 2 to 3 weeks after the infarction. These procedures were repeated 6 months after the infarction. End points were changes in the left ventricular ejection fraction (LVEF), end-diastolic volume, and infarct size.

Citation impact

1,304
total citations
FWCI
78.33
Percentile
100%
References
45
Citations per year

Authors

20

Topics & keywords

Keywords
  • Medicine
  • Ejection fraction
  • Myocardial infarction
  • Cardiology
  • Internal medicine
  • Infarction
  • Percutaneous coronary intervention
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.